Tracking lipid variability may be a reliable method of predicting dementia and cognitive decline among community-dwelling ...

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based ...

An emergency room doctor has shared the 10 early warning signs you or a loved one might have developed Alzheimer's disease - as he urges people to visit their doctors ...

Whether you're curious to explore a healthy brain or brains affected by Alzheimer’s disease, vascular dementia, dementia with Lewy bodies, or Frontotemporal dementia, the choice is yours. Tailoring ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

Two new PET radiotracers have outperformed the only current Food and Drug Administration (FDA) approved radiotracer for ...

A delay in getting to the rapid eye movement (REM) stage of sleep may be linked to Alzheimer's disease and related dementias, ...

The Alzheimer's Accountability and Investment Act (Public Law 118-93), enacted on October 1, 2024, mandates that the National ...

Scientists have recently shown that both the quality and the amount of sleep we get may influence our risk of developing ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...

(Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner ...

There are two kinds of risk factors for dementia: non-modifiable and modifiable. Non-modifiable risk factors are ones that cannot be changed or eliminated, like aging, family history and genetics.